Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
- Conditions
- Ovarian Neoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT00001426
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treatment of Wegener's Granulomatosis With Cyclophosphamide
- Conditions
- VasculitisWegener's Granulomatosis
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 200
- Registration Number
- NCT00001155
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Diffuse Fibrotic Lung Disease
- Conditions
- Pulmonary FibrosisSarcoidosisLung Diseases
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Registration Number
- NCT00000596
Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
- Conditions
- Aplastic Anemia
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 10
- Registration Number
- NCT00004323
- Locations
- 🇺🇸
Center for Health Sciences, Los Angeles, California, United States
Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
- Conditions
- Aplastic Anemia
- Interventions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 224
- Registration Number
- NCT00004474
- Locations
- 🇺🇸
Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Aplastic AnemiaParoxysmal Hemoglobinuria, Nocturnal
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 69
- Registration Number
- NCT00004464
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.